Article

Long-term survival after neoadjuvant low-dose ipilimumab plus high-dose nivolumab in resectable stage III melanoma: the 5-year survival-update and biomarker analysis from the PRADO-trial

2025-07-15

Abstract excerpt

<title>Abstract</title> <p>Neoadjuvant ipilimumab plus nivolumab has become standard therapy for stage III melanoma based on the NADINA trial, though long-term data are lacking. In the phase 2 PRADO cohort of OpACIN-neo (NCT02977052), 99 patients with stage III macroscopic melanoma received this regimen. We report first-time 5-year survival data: 71% event-free survival, 74% relapse-free survival, 79% distant met...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 60961ca5-263f-54ad-994c-b854c6ef73da
DOI: 10.21203/rs.3.rs-7090131/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Long-term survival after neoadjuvant low-dose ipilimumab plus high-dose nivolumab in resectable stage III melanoma: the 5-year survival-update and biomarker analysis from the PRADO-trialDOI 10.21203/rs.3.rs-7090131/v1Read

Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma.Semantic proximity Read

Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma.Semantic proximity Read

Response to high dose ipilimumab plus temozolomide after progression on standard or low dose ipilimumab in advanced melanoma: a retrospective analysisSemantic proximity Read

Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAFV600-mutant resectable melanoma: the randomized phase 2 NeoTrio trial.Semantic proximity Read

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.Semantic proximity Read

TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy.Semantic proximity Read

Neoadjuvant Vidutolimod and Nivolumab in High-Risk Resectable MelanomaSemantic proximity Read

Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial.Semantic proximity Read

A real-world study of adjuvant anti-PD -1 immunotherapy on stage III melanoma with BRAF, NRAS, and KIT mutations.Semantic proximity Read

Nivolumab and Ipilimumab in Metastatic Melanoma Are Associated with Distinct Immune Landscape Changes and Response-Associated ImmunophenotypesSemantic proximity Read

Prognostic biomarkers in melanoma: a 2023 update from clinical trials in different therapeutic scenarios.Semantic proximity Read

Safety and Efficacy of Intratumoral Anti-CTLA4 with Intravenous Anti-PD1Semantic proximity Read